

IGI LABORATORIES, INC  
Form 8-K  
July 02, 2014

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): July 2, 2014**

**IGI LABORATORIES, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**                              **001-08568**                              **01-0355758**  
**(State or other jurisdiction**   **(Commission File Number)**   **(IRS Employer**  
**of incorporation)**                              **Identification No.)**

**105 Lincoln Avenue**  
**Buena, New Jersey 08310**  
**(Address of principal executive offices and zip code)**

**Registrant's telephone number, including area code: (856) 697-1441**

**(Former Name or Former Address, if Changed Since Last Report)**

**Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):**

**.. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)**

**.. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)**

**..Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))**

**..Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))**

**Item 8.01 Other Events.**

On July 2, 2014, IGI Laboratories, Inc. (the “Company”) announced the closing of the Company’s previously announced underwritten public offering of its common stock, including the exercise in full by the underwriters of their over-allotment option to purchase an additional 697,500 shares of common stock. The gross proceeds of the offering, including the exercise of the over-allotment option, were approximately \$26.7 million, before deducting underwriting discounts and commissions and offering expenses payable by the Company. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Neither the filing of the press release as an exhibit to this Current Report on Form 8-K nor the inclusion in the press release of a reference to the Company’s internet address shall, under any circumstances, be deemed to incorporate the information available at the Company’s internet address into this Current Report on Form 8-K. The information available at the Company’s internet address is not part of this Current Report on Form 8-K or any other report filed by it with the Securities and Exchange Commission.

**Item 9.01 Financial Statements and Exhibits.**

(d) The following exhibit is filed with this Report:

**Exhibit No. Description**

99.1 Press release, dated July 2, 2014, announcing the closing of the public offering

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**IGI LABORATORIES, INC.**

By: /s/ Jenniffer Collins  
Name: Jenniffer Collins  
Title: Chief Financial Officer

Date: July 2, 2014